Results 71 to 80 of about 20,070 (218)

Narcolepsy and rapid eye movement sleep

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

Orexin-A and Orexin-B During the Postnatal Development of the Rat Brain [PDF]

Cellular and Molecular Neurobiology, 2009
Orexin-A and orexin-B are hypothalamic neuropeptides isolated from a small group of neurons in the hypothalamus, which project their axons to all major parts of the central nervous system. Despite the extensive information about orexin expression and function at different parts of the nervous system in adults, data about the development and maturation ...
Stoyanova, Irina, Rutten, Wim, le Feber, Jakob   +2 more
openaire   +3 more sources

Ageing‐related modification of sleep and breathing in orexin‐knockout narcoleptic mice

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Narcolepsy type‐1 (NT1) is a lifelong sleep disease, characterised by impairment of the orexinergic system, with a typical onset during adolescence and young adulthood. Since the wake–sleep cycle physiologically changes with ageing, this study aims to compare sleep patterns between orexin‐knockout (KO) and wild type (WT) control mice at ...
Stefano Bastianini, Sara Alvente, Chiara Berteotti, Viviana Lo Martire, Gabriele Matteoli, Elena Miglioranza, Alessandro Silvani, Giovanna Zoccoli   +7 more
wiley   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source

Profiling the sleep architecture of ageing adults using a seven‐state continuous‐time Markov model

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Sleep is a complex biological process regulated by networks of neurons and environmental factors. As one falls asleep, neurotransmitters from sleep–wake regulating neurones work in synergy to control the switching of different sleep states throughout the night. As sleep disorders or underlying neuropathology can manifest as irregular switching,
Jonathon Jacobs, Caitlin E. Martin, Bernard Fuemmeler, Shanshan Chen   +3 more
wiley   +1 more source

Presence of orexin A and orexin 1 receptor in the buffalo prostate

Italian Journal of Animal Science, 2010
The orexins A and B are two peptides discovered initially in the rat lateral hypothalamus involved in the regulation of some body functions such as food intake, sleep/wake cycle, arterial pressure and heart rate. They interact with two receptors defined &
A. Vittoria, F. Russo, G. Petrosino
doaj   +1 more source

Respiratory safety of lemborexant in adult and elderly subjects with moderate‐to‐severe chronic obstructive pulmonary disease

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Lemborexant 10 mg, a dual orexin‐receptor antagonist (DORA), did not elicit respiratory depressant effects, as measured by peripheral oxygen saturation (SpO2) or apnea–hypopnea index (AHI), in subjects with moderate‐to‐severe chronic obstructive pulmonary disease (COPD).
Jocelyn Y. Cheng, Daniel Lorch, Nancy Hall, Margaret Moline   +3 more
wiley   +1 more source

Exogenous Orexin-A Microinjected Into Central Nucleus of the Amygdala Modulates Feeding and Gastric Motility in Rats

Frontiers in Neuroscience, 2020
Orexin-A is a circulating neuropeptide and neurotransmitter that regulates food intake and gastric motility. The central nucleus of the amygdala (CeA), which regulates feeding behavior and gastric function, expresses the orexin-1 receptor.
Tingting Jin, Zhongxin Jiang, Xiao Luan, Zhuling Qu, Feifei Guo, Shengli Gao, Luo Xu, Xiangrong Sun   +7 more
doaj   +1 more source

Targeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof‐Of‐Concept Study of Alixorexton

Journal of Sleep Research, EarlyView.
Orexin 2 receptor agonists have demonstrated that targeting the orexin system may address symptoms of central disorders of hypersomnolence. Results of this phase 1 study support the phase 2 clinical evaluation of oral alixorexton in patients with IH, NT2 and NT1.
Ronald R. Grunstein, Brendon J. Yee, Julia L. Chapman, Jian Eu Tai, Sheila Sivam, Craig Hopkinson, Daniel G. Smith, Alexandra Lovett, Shifang Liu, Sergey Yagoda, Bhaskar Rege   +10 more
wiley   +1 more source

Differential roles of orexin receptors in the regulation of sleep/wakefulness

Frontiers in Endocrinology, 2013
Orexin A and orexin B are hypothalamic neuropeptides that play critical roles in the regulation of sleep/wakefulness, as well as in a variety of physiological functions such as emotion, reward, and energy homeostasis.
Michihiro eMieda, Natsuko eTsujino, Takeshi eSakurai   +2 more
doaj   +1 more source